Overcoming toxicity and side-effects of lipid-lowering therapies

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 3, 2014, Pages 439-452

  Wilkinson, Michael J ^a   Laffin, Luke J ^a   Davidson, Michael H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

atherosclerosis; cardiovascular diseases; drug toxicity; hydroxymethylglutaryl CoA reductase inhibitors; hypercholesterolemia; lipoproteins

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CHOLESTEROL; CHOLESTIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; UBIDECARENONE; VITAMIN D;

ADVERSE DRUG REACTION; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; DRUG TOXICITY; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; MYOPATHY; NEUROLOGIC DISEASE; RISK FACTOR; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; KIDNEY DISEASES; MUSCULAR DISEASES; NERVOUS SYSTEM DISEASES;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; KIDNEY DISEASES; MUSCULAR DISEASES; NERVOUS SYSTEM DISEASES; RISK FACTORS;

EID: 84901297471     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.01.006     Document Type: Review

References (64)

1. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA Guideline on the treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2013
2. C. Baigent, A. Keech, and P.M. Kearney et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 9493 2005 1267 1278
3. T.R. Joy, and R.A. Hegele Narrative review: statin-related myopathy Ann Intern Med 150 12 2009 858 868
4. S.M. Grundy Can statins cause chronic low-grade myopathy? Ann Intern Med 137 7 2002 617 618
5. J.M. McKenney, M.H. Davidson, and T.A. Jacobson et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 8A 2006 89C 94C
6. G.B. Mancini, S. Baker, and J. Bergeron et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference Can J Cardiol 27 5 2011 635 662
7. J.A. Staffa, J. Chang, and L. Green Cerivastatin and reports of fatal rhabdomyolysis N Engl J Med 346 7 2002
8. E. Bruckert, G. Hayem, and S. Dejager et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 6 2005 403 414
9. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs 2012 http://www.fda.gov/drugs/drugsafety/ ucm293101.htm
10. N. Sattar, D. Preiss, and H.M. Murray et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 9716 2010 735 742
11. A.L. Culver, I.S. Ockene, and R. Balasubramanian et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative Arch Intern Med 172 2 2012 144 152
12. S.N. Rajpathak, D.J. Kumbhani, and J. Crandall et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis Diabetes Care 32 10 2009 1924 1929
13. D.J. Freeman, J. Norrie, N. Sattar, and R.D.G. Neely et al. Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 2001 357 362
14. A.A. Carter, T. Gomes, and X. Camacho et al. Risk of incident diabetes among patients treated with statins: population based study BMJ 346 2013 f2610
15. N.L. Zaharan, D. Williams, and K. Bennett Statins and risk of treated incident diabetes in a primary care population Br J Clin Pharmacol 75 4 2013 1118 1124
16. B. McGuinness, J. O'Hare, and D. Craig et al. Statins for the treatment of dementia Cochrane Database Syst Rev 8 2010 CD007514
17. B.F. Vandenberg, and J. Robinson Management of the patient with statin intolerance Curr Atheroscler Rep 12 1 2010 48 57
18. D. Voora, S.H. Shah, and I. Spasojevic et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 17 2009 1609 1616
19. M. Needham, and F.L. Mastaglia Statin myotoxicity: a review of genetic susceptibility factors Neuromuscul Disord 24 1 2014 4 15
20. S.C. Group, E. Link, and S. Parish et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 8 2008 789 799
21. J.F. Ruisinger, J.M. Backes, and C.A. Gibson et al. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance Am J Cardiol 103 3 2009 393 394
22. J.M. Backes, C.V. Venero, and C.A. Gibson et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance Ann Pharmacother 42 3 2008 341 346
23. M. Gadarla, A.K. Kearns, and P.D. Thompson Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins Am J Cardiol 101 12 2008 1747 1748
24. V.G. Athyros, K. Tziomalos, and A.I. Kakafika et al. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients Am J Cardiol 101 4 2008 483 485
25. E.A. Stein, C.M. Ballantyne, and E. Windler et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins Am J Cardiol 101 4 2008 490 496
26. Y. Saito Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals Vasc Health Risk Manag 5 2009 921 936
27. R.E. Morgan, S.E. Campbell, and K. Suehira et al. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers J Acquir Immune Defic Syndr 60 2 2012 158 164
28. J.C. Fruchart, H.B. Brewer Jr., and E. Leitersdorf Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group Am J Cardiol 81 7 1998 912 917
29. H.B. Rubins, S.J. Robins, and D. Collins et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 6 1999 410 418
30. A. Keech, R.J. Simes, and P. Barter et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 9500 2005 1849 1861
31. M. Lee, J.L. Saver, and A. Towfighi et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis Atherosclerosis 217 2 2011 492 498
32. Y.Y. Zhao, M.A. Weir, and M. Manno et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study Ann Intern Med 156 8 2012 560 569
33. T.M. Davis, R. Ting, and J.D. Best et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2 2011 280 290
34. L.R. Pierce, D.K. Wysowski, and T.P. Gross Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy J Am Med Assoc 264 1 1990 71 75
35. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering J Am Med Assoc 251 3 1984 365 374
36. M.H. Davidson, M.A. Dillon, and B. Gordon et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects Arch Intern Med 159 16 1999 1893 1900
37. T.A. Jacobson, A. Armani, and J.M. McKenney et al. Safety considerations with gastrointestinally active lipid-lowering drugs Am J Cardiol 99 6A 2007 47C 55C
38. M. Lukasova, J. Hanson, and S. Tunaru et al. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials Trends Pharmacol Sci 32 12 2011 700 707
39. U. Julius, and S. Fischer Nicotinic acid as a lipid-modifying drug - a review Atheroscler Suppl 14 1 2013 7 13
40. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 17 2013 1279 1291
41. A. Garg, and S.M. Grundy Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus J Am Med Assoc 264 6 1990 723 726
42. A. Pandor, R.M. Ara, and I. Tumur et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials J Intern Med 265 5 2009 568 580
43. C. Baigent, M.J. Landray, and C. Reith et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 9784 2011 2181 2192
44. C.P. Cannon, R.P. Giugliano, and M.A. Blazing et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 5 2008 826 832
45. J. Liu, J. Zhang, and Y. Shi et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials Chin Med 1 2006 4
46. D.J. Becker, R.Y. Gordon, and S.C. Halbert et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial Ann Intern Med 150 12 2009 830 839 W147-9
47. S.C. Halbert, B. French, and R.Y. Gordon et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance Am J Cardiol 105 2 2010 198 204
48. L. Childress, A. Gay, and A. Zargar et al. Review of red yeast rice content and current Food and Drug Administration oversight J Clin Lipidol 7 2 2013 117 122
49. M.H. Frick, O. Elo, and K. Haapa et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 20 1987 1237 1245
50. S. Larsen, N. Stride, and M. Hey-Mogensen et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance J Am Coll Cardiol 61 1 2013 44 53
51. W. Ahmed, N. Khan, and C.J. Glueck et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients Transl Res - J Lab Clin Med 153 1 2009 11 16
52. L. Marcoff, and P.D. Thompson The role of coenzyme Q10 in statin-associated myopathy: a systematic review J Am Coll Cardiol 49 23 2007 2231 2237
53. G. Caso, P. Kelly, and M.A. McNurlan et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins Am J Cardiol 99 10 2007 1409 1412
54. D.A. Bookstaver, N.A. Burkhalter, and C. Hatzigeorgiou Effect of coenzyme Q10 supplementation on statin-induced myalgias Am J Cardiol 110 4 2012 526 529
55. J. Fedacko, D. Pella, and P. Fedackova et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment Can J Physiol Pharmacol 91 2 2013 165 170
56. L. Zlatohlavek, M. Vrablik, and B. Grauova et al. The effect of coenzyme Q10 in statin myopathy Neuro Endocrinol Lett 33 Suppl. 2 2012 98 101
57. J.M. Young, C.M. Florkowski, and S.L. Molyneux et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia Am J Cardiol 100 9 2007 1400 1403
58. M.P. Bogsrud, G. Langslet, and L. Ose et al. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy Scand Cardiovasc J 47 2 2013 80 87
59. B.A. Parker, S.M. Gregory, and L. Lorson et al. A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design J Clin Lipidol 7 3 2013 187 193
60. J.N. Hathcock, and A. Shao Risk assessment for coenzyme Q10 (Ubiquinone) Regul Toxicol Pharmacol 45 3 2006 282 288
61. G.A. Plotnikoff, and J.M. Quigley Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain Mayo Clin Proc 78 12 2003 1463 1470
62. S. Bhattacharyya, K. Bhattacharyya, and A. Maitra Possible mechanisms of interaction between statins and vitamin D QJM - Mon J Assoc Phys 105 5 2012 487 491
63. A. Gupta, and P.D. Thompson The relationship of vitamin D deficiency to statin myopathy Atherosclerosis 215 1 2011 23 29
64. C.J. Glueck, S.B. Budhani, and S.S. Masineni et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance Curr Med Res Opin 27 9 2011 1683 1690